论文部分内容阅读
目的探讨拉米夫定(LAM)联合阿德福韦酯(ADV)治疗老年失代偿期乙型肝炎(乙肝)后肝硬化的疗效及对免疫功能的影响。方法 100例老年失代偿期乙肝后肝硬化患者,按照治疗方案不同分为对照组(44例)和研究组(56例)。对照组采用LAM治疗,研究组采用LAM联合ADV治疗,对比两组临床治疗情况。结果治疗后,两组患者肝功能指标与免疫功能指标均较治疗前明显改善,研究组改善幅度显著优于对照组,差异有统计学意义(P<0.01)。结论 LAM联合ADV治疗老年失代偿期乙肝后肝硬化疗效显著,可有效改善患者肝功能及免疫功能,具有临床实际应用价值。
Objective To investigate the effect of lamivudine (LAM) combined with adefovir dipivoxil (ADV) on the treatment of liver cirrhosis in elderly patients with decompensated hepatitis B (hepatitis B) and its effect on immune function. Methods 100 elderly patients with decompensated hepatitis B after liver cirrhosis were divided into control group (44 cases) and study group (56 cases) according to the different treatment options. The control group was treated with LAM. The study group was treated with LAM combined with ADV, and the clinical treatment was compared between the two groups. Results After treatment, the indexes of liver function and immune function in both groups were significantly improved compared with those before treatment. The improvement rate of the study group was significantly better than that of the control group (P <0.01). Conclusion LAM combined with ADV treatment of elderly patients with decompensated hepatitis B after liver cirrhosis significant effect, can effectively improve the liver function and immune function in patients with clinical practical value.